See Infographic on prescription drug price increases in Medicare Part B
Three U.S. senators are seeking more information from a Florida company that has steadily increased the price of a 40-year-old cancer drug
“I think what happened is they looked at this policy very, very closely and found out it was a loser,” PCMA President Mark Merritt said.
Greater competition is the answer, Mr. Merritt said, and he praised recent efforts by the Food and Drug Administration
Increasing list prices are not correlated with changes in prescription drug rebates.
“This extra year will help to reduce disruptions to Medicare beneficiaries by allowing Part D plans time to adjust their pay-for-performance pharmacy contracting,” PCMA said. “In addition, the delay appropriately prevents premiums from increasing in 2023 on top of rising inflation.”
âWe are simply seeing more activity in the pharmacy space, which is leading to more business,â JC Scott, the head of the Pharmaceutical Care Management Association, the primary lobbying group for PBMs, told STAT. âThereâs more demand for PBM services as a result of that.â
The PBM industry counters that it shouldnât have to report anything. The Pharmaceutical Care Management Association, which represents PBMs, said in its comment letter that the rule goes beyond the agenciesâ statutory authority and asked that âamounts retained by PBMsâ be excluded. âAs a form of PBM compensation, amounts retained by PBMs and not passed through to the plan have a net-zero impact on premiums,â it said.
©2024 PCMA. All Rights Reserved.
